Skip to main content

Table 1 Descriptives and baseline characteristics

From: Secukinumab leads to shifts from stage-based towards response-based disease clusters—comparative data from very early and established psoriatic arthritis

 

All patients (n = 36)

Established PsA (n = 17)

Very Early Disease  (n = 19)

SMD (Established PsA vs. Very Early Disease  )

Demographics

 Age (m ± SD)

50.2 ± 11.5

52.1 ± 9

48.6 ± 13.4

0.304

 Sex (male, %)

58.3%

41.2%

73.7%

0.696

 Disease duration (m ± SD)

10.3 ± 9.4

6.5 ± 5.1

13.9 ± 11.2

0.854

Therapy

 Previous DMARDs (%)

52.8%

82.4%

26.3%

0.696

 cDMARDs (%)

22.2%

47.1%

0%

1.333

 Previous biologics (%)

25%

47.1%

0%

1.081

Clinical characteristics

 VAS pain (m ± SD)

45.4 ± 27.4

64.1 ± 17.5

28.8 ± 23.8

1.686

 VAS global (m ± SD)

59.4 ± 22.2

57.4 ± 23.6

61.3 ± 21.3

0.177

 VAS physician (m ± SD)

37.4 ± 22.3

39.6 ± 15.2

35.4 ± 27.4

0.190

 TJC (m ± SD)

7.4 ± 8.6

12.5 ± 8.7

2.8 ± 5.2

1.354

 SJC (m ± SD)

2.4 ± 3.1

5.1 ± 2.5

0 ± 0

2.848

 DAS-28 ESR (m ± SD)

NA

4.9 ± 1

NA

NA

 DAPSA (m ± SD)

NA

30.8 ± 11.6

NA

NA

 PASI (m ± SD)

6.6 ± 8.6

2 ± 4.4

10.7 ± 9.4

1.185

 BSA% (m ± SD)

9.7 ± 14.9

3.6 ± 11.7

15.2 ± 15.6

0.846

QoL

 PsAID (m ± SD)

4.4 ± 2.2

5.2 ± 2.1

3.7 ± 2.0

0.744

 DLQI (m ± SD)

7.8 ± 6.5

5.4 ± 6.7

10.1 ± 5.7

0.770

 HAQ-DI (m ± SD)

0.5 ± 0.5

0.8 ± 0.5

0.3 ± 0.4

1.141

 PF-SF36 (m ± SD)

69 ± 27

55.3 ± 23.6

81.3 ± 24.1

1.090

 Role physical-SF36 (m ± SD)

53.5 ± 38.8

41.2 ± 37.4

64.5 ± 37.6

0.621

 Role emotional-SF36 (m ± SD)

60.2 ± 44.9

58.8 ± 44.9

61.4 ± 46.2

0.057

 SF – SF36 (m ± SD)

67.7 ± 25.4

64 ± 25.7

71.1 ± 25.4

0.277

 Mental health-SF36 (m ± SD)

60.1 ± 18.5

56 ± 17.1

63.8 ± 19.3

0.427

 Vitality-SF36 (m ± SD)

43.5 ± 22.3

38.2 ± 22.5

48.2 ± 21.6

0.450

 BP-SF36 (m ± SD)

46.9 ± 25.9

32.3 ± 20.2

60 ± 23.6

1.261

 GH-SF36 (m ± SD)

42.2 ± 20.9

35.9 ± 15.4

47.8 ± 23.8

0.593

 PCS-SF36 (m ± SD)

39.5 ± 11.4

33.5 ± 10.3

44.9 ± 9.7

1.143

 MCS-SF36 (m ± SD)

43.3 ± 11.8

43.5 ± 11.1

43.2 ± 12.7

0.024

  1. BP bodily pain, BSA body surface area, cDMARDS concomitant disease modifying anti-rheumatic drugs, DAPSA disease activity in psoriatic arthritis, DAS disease activity score, DLQI dermatology life quality index, DMARDs disease modifying anti-rheumatic drugs, GH general health, HAQ health assessment questionnaire, MCS mental component summary, PASI psoriasis area and severity index, PCS physical component summary, PF physical functioning, PsA psoriatic arthritis, PsAID psoriatic arthritis impact of disease, SD standard deviation, SF social functioning, SF36 short form 36, SJC swollen joint count, SMD standard mean difference, TJC tender joint count, VAS visual analog scale
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us